Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf‐dependent and ‐independent manners in Mice

Tetsuhiro Chiba, Atsuyoshi Seki, Ryutaro Aoki, Hitoshi Ichikawa, Masamitsu Negishi, Satoru Miyagi, Hideyuki Oguro, Atsunori Saraya, Akihide Kamiya, Hiromitsu Nakauchi, Osamu Yokosuka, Atsushi Iwama – 26 August 2010 – We previously reported that forced expression of Bmi1 (B lymphoma Moloney murine leukemia virus insertion region 1 homolog) in murine hepatic stem/progenitor cells purified from fetal liver enhances their self‐renewal and drives cancer initiation.

Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells

Avidan U. Neumann, Sandra Phillips, Idit Levine, Samreen Ijaz, Harel Dahari, Rachel Eren, Shlomo Dagan, Nikolai V. Naoumov – 26 August 2010 – Antibodies are thought to exert antiviral activities by blocking viral entry into cells and/or accelerating viral clearance from circulation. In particular, antibodies to hepatitis B virus (HBV) surface antigen (HBsAg) confer protection, by binding circulating virus.

Expanding access to hepatitis C virus treatment—Extension for Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care

Sanjeev Arora, Summers Kalishman, Karla Thornton, Denise Dion, Glen Murata, Paulina Deming, Brooke Parish, John Brown, Miriam Komaromy, Kathleen Colleran, Arthur Bankhurst, Joanna Katzman, Michelle Harkins, Luis Curet, Ellen Cosgrove, Wesley Pak – 26 August 2010 – The Extension for Community Healthcare Outcomes (ECHO) Model was developed by the University of New Mexico Health Sciences Center as a platform to deliver complex specialty medical care to underserved populations through an innovative educational model of team‐based interdisciplinary development.

Outcome of sustained virological responders with histologically advanced chronic hepatitis C

Timothy R. Morgan, Marc G. Ghany, Hae‐Young Kim, Kristin K. Snow, Mitchell L. Shiffman, Jennifer L. De Santo, William M. Lee, Adrian M. Di Bisceglie, Herbert L. Bonkovsky, Jules L. Dienstag, Chihiro Morishima, Karen L. Lindsay, Anna S. F. Lok, and the HALT‐C Trial Group – 26 August 2010 – Retrospective studies suggest that subjects with chronic hepatitis C and advanced fibrosis who achieve a sustained virological response (SVR) have a lower risk of hepatic decompensation and hepatocellular carcinoma (HCC).

Subscribe to